KLOW Protocol
Also known as: KLOW
Four-Peptide Regenerative Blend
Overview
KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).
Key benefits
- Theoretical synergistic multi-pathway tissue repair
- Anti-inflammatory effects across multiple mechanisms
- Cellular regeneration support
- Convenience of single injection dosing
- KPV may reduce injection site reactions versus GLOW
Mechanism of action
Each peptide contributes distinct biological pathways: GHK-Cu modulates gene expression for tissue repair, TB-500 enhances cellular migration and wound healing, BPC-157 upregulates growth factors for tissue regeneration, and KPV inhibits NF-κB inflammatory pathway.
Molecular data
- Type
- Fixed-ratio peptide combination
Sequence
GHK-Cu + TB-500 + BPC-157 + KPV (5:1:1:1 ratio)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Primary Applications
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200mcg total daily | Once daily evening | — |
| — | 200-500mcg total | Once daily | — |
| — | Per standard dosing | 4-6 weeks on, 2-4 weeks off | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site reactions (common even with KPV)
- Individual responses vary widely
Rare side effects
- Signs of copper toxicity with prolonged use
Contraindications
- No safety studies on four-peptide combination
- Long-term effects completely unknown
- FDA has not approved any component for therapeutic use
References
Primary literature and clinical-trial data informing this entry.